Register

Neurology

Vasculitis   

Questions discussed in this category

When do you consider tapering tocilizumab in patients with GCA in remission?
1 Answer available
How would you approach the treatment of checkpoint inhibitor mediated temporal arteritis?
Is there role for IVIG? Would you alter the dose or time course of steroid therapy?
2 Answers available
Can giant cell arteritis present with a partial cranial neuropathy?
3 Answers available
Do you always perform temporal artery biopsy in patients with positive inflammatory markers and high clinical suspicion of GCA?
2 Answers available
Is either ESR or CRP more sensitive or specific for the diagnosis of GCA?
Additionally, what is the current role for temporal artery ultrasound in workup for GCA?
3 Answers available
What is the utility in repeating a temporal ultrasound (US) in a previously US diagnosed positive GCA patient who has received treatment and is presenting with recurrent GCA symptoms?
1 Answer available
When is brain biopsy useful/warranted as part of the diagnostic work-up in patients with suspected primary CNS angiitis?
3 Answers available
What is your steroid-sparing agent of choice to treat GCA given the current tocilizumab shortage?
Thoughts on sarilumab vs methotrexate, or just treat with steroids alone
1 Answer available
What is your approach to checking serum vWF antigen levels in adult patients with CNS vasculitis for monitoring disease activity?
Small study in pediatric PACNS have evaluated this as a potential marker (Cellucci et al., PMID 22740622)
1 Answer available
What is your approach for treating mononeuritis multiplex in patients with ANCA vasculitis?
Specifically, do you reach for Rituximab or cyclophosphamide?
1 Answer available
Are there features of a nerve biopsy that help distinguish late nerve damage from vasculitis versus from a demyelinating disease?
1 Answer available
Do you treat HIV/AIDS-associated CNS vasculitis with antiretrovirals alone or in combination with steroids?
1 Answer available
How do you monitor response to treatment in patients with mononeuritis multiplex secondary to vasculitis?
Given the slow recovery of nerve damage, what would you expect to see on a repeat EMG after treatment? Continued denervation or just sequelae of past ...
1 Answer available


Papers discussed in this category

Front Neurol, 2019 Jun 06
Primary Angiitis of the Central Nervous System: New Potential Imaging Techniques and Biomarkers in Blood and Cerebrospinal Fluid.
N Engl J Med,
Trial of Tocilizumab in Giant-Cell Arteritis.
Lancet, 2016 Mar 04
Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
Arthritis Rheum,
Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.
Seminars in arthritis and rheumatism, 2012-06
Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis.
Arthritis Rheumatol, 2021 Jul 08
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.
Ann Rheum Dis, 2019 Jul 03
2018 Update of the EULAR recommendations for the management of large vessel vasculitis.
Mayo Clin Proc,
My Treatment Approach to Giant Cell Arteritis.
Ann Rheum Dis, 2021 Jul 02
Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis.
Arthritis Care Res (Hoboken), 2020 May 19
Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta-Analysis.
J Rheumatol, 2021 Feb 15
Real-world Risk of Relapse of Giant Cell Arteritis Treated With Tocilizumab: A Retrospective Analysis of 43 Patients.
Rheumatology (Oxford),
Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis.

Related Topics in Neurology

Copyright © 2025 theMednet
All Rights Reserved.